ABUS
Arbutus Biopharma Corp
$4.26
-0.70%
$841.5M
No data for this timeframe.
Vol
Market Cap$841.5M
Cap SizeSmall Cap
Inst. Holders50 funds
Inst. Value$375.5M
Inst. Activity5 buys / 2 sells
Reddit Sentiment55° Neutral
SEC Reports4
Press Releases1
Recent Activity
Jun 12, 2026
SEC
A mixed institutional cluster in ABUS for Q3 2024 shows 6 buyers (net +$6.2M) led by Schwab and Citadel doubling their p
INST-CLUSTER — Impact 4/10
Jun 10, 2026
short_volume
Short Volume: ABUS — 79.9% short (0.4M / 0.6M)
Short: 441,932 | Exempt: 219 | TRF Vol: 553,111 | Short Ratio: 79.9% | Off-exchange volume (dark poo
Jun 8, 2026
Insider
Sawhney Roger was granted 78,800 shares
Director
Jun 8, 2026
Insider
Beardsley Robert A was granted 78,800 shares
Director
May 13, 2026
SEC
Arbutus reported Q1 2026 GAAP net income of $169.7M ($0.87 diluted EPS), a massive swing from a $24.5M loss in Q1 2025,
8-K — Impact 7/10
May 13, 2026
SEC
Arbutus reported Q1 2026 GAAP EPS of $0.87 (diluted), a massive beat vs. consensus of -$0.06, driven by $178.7M in licen
PRESS-RELEASE — Impact 8/10
Feb 2, 2026
Insider
Nguyen Tuan was granted 73,500 shares
Chief Financial Officer
Inst.
Rubric Capital Management LP — DOUBLED
6,626,389 shares ($29.8M)
Price Targets
Historical data — last covering-analyst action Nov 2025. No current recommendation available.
$5.08 (Nov 2025)
Current $4.26
Low $4.88
Median $4.95
High $5.40
3 analysts
$4.88
$5.40
Analyst Ratings
3Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Nov 14, 2025 | Chardan Capital | MAINTAIN | Buy → Buy |
| Aug 11, 2025 | Chardan Capital | MAINTAIN | Buy → Buy |
| Mar 28, 2025 | Chardan Capital | MAINTAIN | Buy → Buy |
| Jan 21, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Nov 20, 2024 | Chardan Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.06 ▲ +1.8% | $-0.06 — $-0.06 | -499% YoY | 1 |
| Next Q | $-0.06 ▲ +1.8% | $-0.06 — $-0.06 | 2% YoY | 1 |
| Current FY | $-0.23 ▲ +1.1% | $-0.23 — $-0.22 | 3% YoY | 2 |
| Next FY | $-0.12 | $-0.12 — $-0.12 | -112% YoY | 1 |
Latest Reports
MIXED
INST-CLUSTER
4/10
A mixed institutional cluster in ABUS for Q3 2024 shows 6 buyers (net +$6.2M) led by Schwab and Citadel doubling their p
Jun 12, 2026
BULLISH
8-K
7/10
Arbutus reported Q1 2026 GAAP net income of $169.7M ($0.87 diluted EPS), a massive swing from a $24.5M loss in Q1 2025,
May 13, 2026
BULLISH
Press
9/10
Arbutus Biopharma reported improved financials for 2025 with a narrowed net loss and strong cash position, driven by cos
Mar 23, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | DOUBLED |
| MORGAN STANLEY | $116.5M | — |
| BlackRock, Inc. | $58.4M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $30.1M | — |
| Rubric Capital Management LP | $29.8M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 8, 2026 | Sawhney Roger | A | $0.00 |
| Jun 8, 2026 | Beardsley Robert | A | $0.00 |
| Feb 2, 2026 | Nguyen Tuan | A | $0.00 |
| Feb 2, 2026 | Nguyen Tuan | A | $0.00 |
| Feb 2, 2026 | Androski Lindsay | A | $0.00 |
Reddit Sentiment
55°
Neutral
Bearish
Neutral
Bullish
50 institutional holders with $375.5M total value (83,445,839 shares) as of 2026-Q1. Top holders: ROYAL, MORGAN, BlackRock,. Net buying activity: 5 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 109 | $0.00 | 0.0% | DOUBLED +329.3% |
| 2 | MORGAN STANLEY | 25,891,480 | $116.5M | 31.0% | — |
| 3 | BlackRock, Inc. | 12,966,946 | $58.4M | 15.5% | — |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 6,688,911 | $30.1M | 8.0% | — |
| 5 | Rubric Capital Management LP | 6,626,389 | $29.8M | 7.9% | DOUBLED +320.6% |
| 6 | STATE STREET CORP | 6,342,510 | $28.5M | 7.6% | ADD +44.2% |
| 7 | BARCLAYS PLC | 4,316,095 | $19.4M | 5.2% | TRIM -30.1% |
| 8 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,664,941 | $12.0M | 3.2% | TRIM -38.6% |
| 9 | Legal & General Group Plc | 2,401,389 | $10.8M | 2.9% | DOUBLED +1856.1% |
| 10 | Woodline Partners LP | 2,010,172 | $9.0M | 2.4% | DOUBLED +173.3% |
| 11 | BANK OF AMERICA CORP /DE/ | 1,683,628 | $7.6M | 2.0% | ADD +26.3% |
| 12 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,401,157 | $6.3M | 1.7% | — |
| 13 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,392,024 | $6.3M | 1.7% | — |
| 14 | GOLDMAN SACHS GROUP INC | 1,100,434 | $5.0M | 1.3% | — |
| 15 | VANGUARD FIDUCIARY TRUST CO | 1,063,054 | $4.8M | 1.3% | — |
| 16 | CITIGROUP INC | 898,421 | $4.0M | 1.1% | — |
| 17 | BANK OF MONTREAL /CAN/ | 782,763 | $3.5M | 0.9% | ADD +27.5% |
| 18 | CITADEL ADVISORS LLC | 677,138 | $3.0M | 0.8% | ADD +61.0% |
| 19 | WELLINGTON MANAGEMENT GROUP LLP | 440,924 | $2.0M | 0.5% | — |
| 20 | Hudson Bay Capital Management LP | 350,000 | $1.6M | 0.4% | TRIM -48.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Rubric Capital Management LP | DOUBLED | 1,575,376 | 6,626,389 | +320.6% | $29.8M | 2026-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | TRIM | 4,339,941 | 2,664,941 | -38.6% | $12.0M | 2026-Q1 |
| Legal & General Group Plc | DOUBLED | 122,761 | 2,401,389 | +1856.1% | $10.8M | 2026-Q1 |
| Hudson Bay Capital Management LP | TRIM | 675,000 | 350,000 | -48.1% | $1.6M | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | ADD | 2,399 | 3,766 | +57.0% | $16.9K | 2026-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | DOUBLED | 837 | 1,869 | +123.3% | $8.4K | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | 89,216 | 115,990 | +30.0% | $522.00 | 2026-Q1 |
| STATE STREET CORP | ADD | 4,098,318 | 5,908,211 | +44.2% | $28.4M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 1,450,822 | 1,832,704 | +26.3% | $8.8M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 95,451 | 167,021 | +75.0% | $803.4K | 2025-Q4 |
| BALYASNY ASSET MANAGEMENT L.P. | ADD | 107,665 | 141,646 | +31.6% | $681.3K | 2025-Q4 |
| FMR LLC | ADD | 89,464 | 136,556 | +52.6% | $656.8K | 2025-Q4 |
| Zurcher Kantonalbank (Zurich Cantonalbank) | ADD | 100,338 | 128,315 | +27.9% | $617.2K | 2025-Q4 |
| Rafferty Asset Management, LLC | DOUBLED | 53,008 | 117,032 | +120.8% | $562.9K | 2025-Q4 |
| STATE OF WISCONSIN INVESTMENT BOARD | DOUBLED | 12,863 | 92,769 | +621.2% | $446.2K | 2025-Q4 |
| GROUP ONE TRADING LLC | ADD | 45,794 | 58,416 | +27.6% | $281.0K | 2025-Q4 |
| Mitsubishi UFJ Asset Management Co., Ltd. | TRIM | 73,690 | 54,066 | -26.6% | $257.9K | 2025-Q4 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | NEAR_EXIT | 159,118 | 35,116 | -77.9% | $168.9K | 2025-Q4 |
| ExodusPoint Capital Management, LP | TRIM | 82,377 | 30,503 | -63.0% | $146.7K | 2025-Q4 |
| TEACHER RETIREMENT SYSTEM OF TEXAS | TRIM | 34,969 | 21,179 | -39.4% | $101.9K | 2025-Q4 |
| Mirae Asset Global Investments Co., Ltd. | ADD | 7,411 | 9,346 | +26.1% | $45.0K | 2025-Q4 |
| Allworth Financial LP | DOUBLED | 115 | 2,043 | +1676.5% | $9.8K | 2025-Q4 |
| PNC FINANCIAL SERVICES GROUP, INC. | TRIM | 1,550 | 837 | -46.0% | $4.0K | 2025-Q4 |
| Daiwa Securities Group Inc. | NEAR_EXIT | 14,495 | 395 | -97.3% | $2.00 | 2025-Q4 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | ADD | 2,575,941 | 5,014,941 | +94.7% | $22.8M | 2025-Q3 |
4 unique insiders with 6 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 8, 2026 | Sawhney Roger | Director | AWARD | 78,800 | — | — |
| Jun 8, 2026 | Beardsley Robert A | Director | AWARD | 78,800 | — | — |
| Feb 2, 2026 | Nguyen Tuan | Chief Financial Officer | AWARD | 73,500 | — | — |
| Feb 2, 2026 | Nguyen Tuan | Chief Financial Officer | AWARD | 188,400 | — | — |
| Feb 2, 2026 | Androski Lindsay | President and CEO | AWARD | 28,000 | — | — |
| Feb 2, 2026 | Androski Lindsay | President and CEO | AWARD | 71,700 | — | — |
4 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 1 mixed, 0 neutral. Avg impact: 6.5/10.
MIXED
INST-CLUSTER
4/10
A mixed institutional cluster in ABUS for Q3 2024 shows 6 buyers (net +$6.2M) led by Schwab and Cita
Jun 12, 2026
BULLISH
8-K
7/10
Arbutus reported Q1 2026 GAAP net income of $169.7M ($0.87 diluted EPS), a massive swing from a $24.
May 13, 2026
BULLISH
PRESS-RELEASE
8/10
Arbutus reported Q1 2026 GAAP EPS of $0.87 (diluted), a massive beat vs. consensus of -$0.06, driven
May 13, 2026
BULLISH
8-K
7/10
Arbutus Biopharma announced that the FDA has granted Fast Track designation for its investigational
Apr 15, 2026
Historical analyst distribution (last covering-analyst action Nov 2025): 89% buy across 9 analysts — 3 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Nov 2025. No current recommendation available.
$5.08 mean target (Nov 2025)
$4.88 Low
$5.40 High
| Metric | Value |
|---|---|
| Current Price | $4.26 |
| Target Low | $4.88 |
| Target Mean | $5.08 |
| Target Median | $4.95 |
| Target High | $5.40 |
| # Analysts | 3 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.06 | $-0.06 | $-0.06 | -499.1% | +1.8% | 0↑ 1↓ | $0.0B | -93.5% | 1 |
| Next Q 2026-09-30 |
$-0.06 | $-0.06 | $-0.06 | 1.8% | +1.8% | 0↑ 1↓ | $0.0B | 29.7% | 1 |
| Current FY 2026-12-31 |
$-0.23 | $-0.23 | $-0.22 | 2.7% | +1.1% | 1↑ 0↓ | $0.2B | 1188.1% | 2 |
| Next FY 2027-12-31 |
$-0.12 | $-0.12 | $-0.12 | -112.0% | — | 1↑ 0↓ | $0.0B | -98.5% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.055 | |
| 7d ago | $-0.056 | +0.001 |
| 30d ago | $-0.056 | +0.001 |
| 60d ago | $-0.056 | +0.001 |
| 90d ago | $-0.056 | +0.001 |
7 analyst firms have rated this stock: 6 upgrades, 2 downgrades, 2 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Nov 14, 2025 | Chardan Capital | MAINTAIN | Buy | Buy |
| Aug 11, 2025 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 28, 2025 | Chardan Capital | MAINTAIN | Buy | Buy |
| Jan 21, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 20, 2024 | Chardan Capital | MAINTAIN | Buy | Buy |
| Nov 18, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 7, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 7, 2024 | Chardan Capital | MAINTAIN | Buy | Buy |
| Sep 5, 2024 | Jefferies | MAINTAIN | Buy | Buy |
| Aug 2, 2024 | JMP Securities | MAINTAIN | Market Outperform | Market Outperform |
| Jun 7, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 6, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 5, 2024 | Chardan Capital | MAINTAIN | Buy | Buy |
| May 3, 2024 | Chardan Capital | REITERATE | Buy | Buy |
| Apr 4, 2024 | JMP Securities | REITERATE | Market Outperform | Market Outperform |
| Mar 1, 2024 | Chardan Capital | REITERATE | Buy | Buy |
| Mar 1, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Sep 12, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 4, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 4, 2023 | Chardan Capital | REITERATE | Buy | Buy |
| Jul 11, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jul 6, 2023 | JMP Securities | REITERATE | Market Outperform | Market Outperform |
| Jun 22, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 22, 2023 | Chardan Capital | REITERATE | Buy | Buy |
| May 5, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Apr 28, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Apr 5, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Mar 29, 2023 | JMP Securities | REITERATE | — | Market Outperform |
| Mar 20, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Mar 3, 2023 | Chardan Capital | REITERATE | — | Buy |
| Mar 3, 2023 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Nov 10, 2022 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Jun 28, 2022 | JMP Securities | MAINTAIN | — | Market Outperform |
| Mar 14, 2022 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Mar 4, 2022 | Chardan Capital | MAINTAIN | — | Buy |
| Feb 2, 2022 | Jefferies | UPGRADE | Hold | Buy |
| Nov 8, 2021 | JMP Securities | MAINTAIN | — | Market Outperform |
| Dec 17, 2020 | HC Wainwright & Co. | INITIATE | — | Buy |
| Jul 24, 2020 | Baird | DOWNGRADE | Outperform | Neutral |
| May 19, 2020 | Wedbush | UPGRADE | Neutral | Outperform |
| Mar 27, 2020 | Baird | MAINTAIN | — | Outperform |
| Mar 6, 2020 | Chardan Capital | UPGRADE | Neutral | Buy |
| Feb 20, 2020 | Baird | INITIATE | — | Outperform |
| Feb 5, 2020 | JMP Securities | UPGRADE | Market Perform | Market Outperform |
| Jan 9, 2020 | B. Riley Securities | MAINTAIN | — | Buy |
| Oct 4, 2019 | Chardan Capital | DOWNGRADE | Buy | Neutral |
| Oct 16, 2018 | B. Riley Securities | UPGRADE | Neutral | Buy |
| Oct 15, 2018 | Wedbush | UPGRADE | Underperform | Neutral |
| Aug 13, 2018 | B. Riley Securities | MAINTAIN | Neutral | Neutral |
| Aug 13, 2018 | Wedbush | MAINTAIN | Neutral | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
55°
Neutral
Bearish
Neutral
Bullish
7 mentions
1 bullish
0 bearish
6 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 4, 2026 | 2 | 50° Neutral | 0 | 0 | 2 |
| Mar 4, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 4, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Mar 4, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 4, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Mar 3, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
What do you think about ABUS??
▲ 1
💬 1
⚡ 0.5
What do you think about ABUS??
▲ 1
💬 1
⚡ 0.5
ABUS Settlement in Moderna Lawsuit!
▲ 1
💬 0
⚡ 0.5
ABUS Reaches Settlement with Moderna!!
▲ 1
💬 0
⚡ 0.5
Big Ruling for ABUS in Moderna Lawsuit
▲ 1
💬 1
⚡ 0.5
Jun 10, 2026
short_volume
Short Volume: ABUS — 79.9% short (0.4M / 0.6M)
Short: 441,932 | Exempt: 219 | TRF Vol: 553,111 | Short Ratio: 79.9% | Off-exchange volume (dark pool + OTC)
May 13, 2026
earnings
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p align="center"><strong>Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna</
Apr 30, 2026
earnings_calendar
ABUS Q1 2026 Earnings Scheduled — 2026-04-30
Apr 29, 2026
Clinical Trial
Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection
Phase Phase 2 — COMPLETED
Apr 27, 2026
short_volume
Short Volume: ABUS — 62.1% short (0.4M / 0.6M)
Short: 352,835 | Exempt: 50 | TRF Vol: 568,045 | Short Ratio: 62.1% | Off-exchange volume (dark pool + OTC)
Apr 15, 2026
other
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
<p align="center"><strong>Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran</strong></p>
Apr 10, 2026
short_interest
FTD: ABUS — 159,245 shares ($0.7M) failed to deliver
Settlement: 20260410, Price: $4.30, FTD Value: $684,753.5, ARBUTUS BIOPHARMA CORP COM STK
Mar 25, 2026
earnings_calendar
ABUS Q4 2025 Earnings After Market Close — 2026-03-25
Mar 24, 2026
short_volume
Short Volume: ABUS — 72.0% short (0.5M / 0.6M)
Short: 464,421 | Exempt: 0 | TRF Vol: 644,685 | Short Ratio: 72.0% | Off-exchange volume (dark pool + OTC)
Mar 23, 2026
earnings
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
<p align="center"><strong>Strong financial position with cash, cash equivalents </strong><strong>and marketable securities of $91.5M as of December 20
Mar 23, 2026
short_volume
Short Volume: ABUS — 55.4% short (0.9M / 1.5M)
Short: 853,424 | Exempt: 0 | TRF Vol: 1,540,478 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
Mar 3, 2026
other
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
<p>BASEL, Switzerland and VANCOUVER, British Columbia, March 03, 2026 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company
Feb 26, 2026
earnings_calendar
ABUS Q4 2025 Earnings After Market Close — 2026-02-26
Feb 18, 2026
short_interest
FTD: ABUS — 199,930 shares ($0.8M) failed to deliver
Settlement: 20260218, Price: $4.17, FTD Value: $833,708.1, ARBUTUS BIOPHARMA CORP COM STK